Evaluation of the antiparasitic activities of imidazol-2-ylidene-gold(I) complexes by Koko, Waleed S. et al.
Arch Pharm. 2020;353:e1900363. wileyonlinelibrary.com/journal/ardp | 1 of 8
https://doi.org/10.1002/ardp.201900363
Received: 4 December 2019 | Revised: 20 February 2020 | Accepted: 25 February 2020
DOI: 10.1002/ardp.201900363
F U L L PA P E R
Evaluation of the antiparasitic activities of
imidazol‐2‐ylidene–gold(I) complexes
Waleed S. Koko1 | Jana Jentzsch2 | Hussein Kalie3 | Rainer Schobert3 |
Klaus Ersfeld2 | Ibrahim S. Al Nasr1,4 | Tariq A. Khan5 | Bernhard Biersack3
1College of Science and Arts in Ar Rass, Qassim
University, Ar Rass, Saudi Arabia
2Laboratory of Molecular Parasitology,
University of Bayreuth, Bayreuth, Germany
3Organic Chemistry Laboratory, University of
Bayreuth, Bayreuth, Germany
4College of Science and Arts in Unaizah,
Qassim University, Unaizah, Saudi Arabia
5College of Applied Health Sciences in Ar Rass,
Qassim University, Ar Rass, Saudi Arabia
Correspondence
Bernhard Biersack, Organic Chemistry
Laboratory, University of Bayreuth,
Universitätsstrasse 30, 95440 Bayreuth,
Germany.
Email: bernhard.biersack@yahoo.com
Funding information
Qassim University, Grant/Award Number:
cosao‐bs‐2019‐2‐2‐1‐5619; Deutsche
Forschungsgemeinschaft,
Grant/Award Number: Scho 402/12‐2
Abstract
A series of cationic gold(I)–carbene complexes with various 4,5‐diarylimidazolylidene
ligands were either newly prepared or repurposed for testing against protozoal
Leishmania major, Toxoplasma gondii, and Trypanosoma brucei parasites. The syntheses of
the new complexes 1b and 1c were described. Ferrocene compound 1a showed the
highest activities against L. major amastigotes and T. gondii and distinct selectivity for T.
gondii cells when compared with the activity against nonmalignant Vero cells. The
ferrocene derivatives 1a–c are generally more active against the L. major amastigotes
and the T. gondii tachyzoites than the other tested anisyl gold complexes and the
approved drugs atovaquone and amphotericin B. Compounds 1a and 1e showed the
highest selectivities for L. major amastigotes. Compounds 1d and 1f showed the highest
selectivities for L. major promastigotes; 1f was the most active compound against L.
major promastigotes of this series of compounds. The 3,4,5‐trimethoxyphenyl analog 1b
also exhibited a much greater selectivity for T. b. brucei cells when compared with its
activity against human HeLa cells.
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1 | INTRODUCTION
New, efficient drugs for the treatment of parasitic diseases are
sought‐after, and numerous efforts to identify antiparasitic drugs
against neglected tropical diseases (NTDs) are already being made.[1]
Both locals and travelers in tropical and subtropical countries are in
danger of infection by NTDs, which will likely spread to further re-
gions in the near future due to the ongoing climate change.[2]
Metal‐based drugs have been approved for the therapy of many
diseases and represent a prospering field of drug design.[3] The gold
complex auranofin is a prominent example that is applied for the
treatment of rheumatoid arthritis.[4] Gold complexes with antiparasitic
activities have also been disclosed.[5] The X‐ray structure of auranofin
bound to Leishmania infantum trypanothione reductase revealed a dual
mode of inhibition by this drug.[6] In addition, there is a continuously
growing number of gold N‐heterocyclic carbene (NHC) complexes with
potent biological effects, including anticancer and antiparasitic activ-
ities.[7] Mechanistically, gold–carbene complexes can inhibit thioredoxin
reductase or interact with DNA (e.g., with DNA G quadruplexes).[8–11]
The high antitrypanosomal and parasite cytoskeleton‐damaging activ-
ities of cationic gold(I)–NHC complexes, such as 1a, were reported
previously.[12] Complex 1a was found to be distinctly more active
against Trypanosoma brucei cells than against human cells, including
cancer cells. These antiparasitic effects are not surprising as other
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ferrocene derivatives have previously shown activities against various
parasites.[13–15] In addition, imidazoles, on their own, also displayed
distinct antimicrobial and antiparasitic activities.[16,17] We now eval-
uated the scope and structure dependence of the antiparasitic effects
of a series of known and new gold(I)–NHC complexes of our lab on the
protozoal parasites Leishmania major, T. brucei (both kinetoplastid
parasites), and Toxoplasma gondii (apicomplexan parasite). Some of the
known gold complexes used in this study have already shown in vivo
activity against tumor xenografts with good tolerability by the labora-
tory animals and, thus, these complexes are suitable for repurposing
against parasites.[18,19]
2 | RESULTS AND DISCUSSION
The known complexes 1a and 1d–g were prepared according to lit-
erature procedures (Figure 1).[18,19] The new complexes 1b and 1c
were prepared accordingly and tested to assess the influence of
methoxy substituents on the activity against and the selectivity for
protozoal parasites (Scheme 1). The reaction of ferrocenecarbox-
aldehyde with ethyl amine and TosMIC reagents 2b and 2c, respec-
tively, afforded the N‐ethyl‐imidazoles 3b and 3c in good yields. High
yield alkylation with ethyl iodide was followed by quantitative con-
version of the iodides 4b and 4c to the BF4 salts 5b and 5c. Finally,
reaction of 5b and 5c with Ag2O and transmetallation with 0.5 equiv.
Au(DMS)Cl led to the target complexes 1b and 1c as brown solids in
good yields.
The complexes 1a–g (Figure 1) were initially tested for their ac-
tivity against T. gondii tachyzoites (Table 1). The ferrocene derivatives
1a–c showed distinctly higher activities against T. gondii (EC50 =
0.013–0.046 µM) than the anisyl derivatives 1d–g (EC50 = 0.116–
0.678 µM). Complex 1a exhibited the highest activity of all test com-
pounds. The ferrocenes 1a–c also showed a reasonable selectivity for
T. gondii cells (best for 1a, selectivity index [SI] = 28.1) versus
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SCHEME 1 Synthesis of the target compounds. Reagents and
conditions: (i) Ferrocenecarboxaldehyde, EtNH2 (2M in THF), AcOH,
EtOH, reflux, 1 hr, then K2CO3, EtOH, reflux, 2 hr, 74–79%;
(ii) EtI, MeCN, 85°C, 24 hr, 97–100%; (iii) NaBF4, acetone, rt, 24 hr,
100%; (iv) Ag2O, CH2Cl2/MeOH (1:1), rt, 5 hr, then Au(DMS)Cl,
CH2Cl2/MeOH (1:1), rt, 24 hr, 71–79%
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nonmalignant Vero cells. Among the anisyl complexes 1d–g, the
N‐ethyl 3,4,5‐trimehoxyphenyl derivative 1e is more selective than
the analogous N‐methyl derivative 1d, indicating an influence by the
N‐alkyl group. Such an influence was not observed for the
3‐halo‐4,5‐dimethoxyphenyl derivatives 1f and 1g. Compounds 1a–c
were also more active than the positive control atovaquone (ATO),
which is an approved drug for the treatment of toxoplasmosis.
The activity of complexes 1a–g against L. major promastigotes
and amastigotes was also determined (Table 2). The ferrocenes 1a–c
were the most efficient growth inhibitors of the L. major amastigotes
with complex 1a showing the highest activity (EC50 = 0.11 µM) and a
slight selectivity for the amastigotes (SI = 3.32). However, anisyl‐NHC
complex 1e, while being the second least active compound against
amastigotes, showed the highest selectivity for them (SI = 12.8). The
anisyl‐NHC complexes 1d and 1f were slightly more active than the
ferrocenes against L. major promastigotes and less active against
the amastigotes. For approved antileishmanial drugs, a high activity
against amastigotes was observed and other drug candidates also
showed higher activity against L. major amastigotes than against
promastigotes.[20,21] When compared with the positive control
amphotericin B (AmB), complexes 1a–d showed higher activities both
against the promastigotes and against the amastigotes. In addition,
compound 1f was more active than AmB against the promastigotes,
and 1g against the amastigotes. Complex 1e showed virtually the
same activity as AmB against amastigotes and considerable
selectivity.
Compounds 1a and 1e were already described by our groups
as antitrypanosomal compounds.[12] Hence, the new ferrocenes
1b and 1c, which are close analogs of 1a, were selected and also
tested for their trypanocidal activity against bloodstream‐form T.
b. brucei parasites by the Alamar Blue (AB) assay. The obtained
results were compared with those previously observed for 1a and
1e (Table 3).[12] In particular, the new complex 1b exhibited high
activity against T. b. brucei (IC50 = 5 nM) and a high selectivity for
T. b. brucei cells versus human HeLa cervix carcinoma cells. The
selectivity of 1b (SI = 168) for T. b. brucei exceeded even those
of 1a (SI = 148) and the 4‐anisyl‐5‐(3,4,5‐trimethoxyphenyl)‐
imidazol‐2‐ylidene complex 1e. Among the new ferrocenes, the
3,4,5‐trimethoxyphenyl group of 1b proved to be more conducive
to overall activity against and selectivity for the parasite than the
anisyl group of 1c.
TABLE 1 Inhibitory concentrations IC50 (in µM)
a of the test
compounds 1a–g when applied to cells of the Vero (African green
monkey kidney epithelial) cell line, effective concentrations EC50
a
when applied to cells of Toxoplasma gondii
Compd. EC50 (T. gondii) IC50 (Vero) SI (Vero/T. gondii)
b
1a 0.013 ± 0.002 0.365 ± 0.054 28.1
1b 0.046 ± 0.008 0.662 ± 0.083 14.4
1c 0.041 ± 0.006 0.458 ± 0.070 11.2
1d 0.195 ± 0.012 0.720 ± 0.121 3.69
1e 0.678 ± 0.091 5.52 ± 1.310 8.14
1f 0.313 ± 0.007 0.573 ± 0.063 1.83
1g 0.116 ± 0.033 0.220 ± 0.046 1.90
ATO 0.07 ± 0.006 9.5 ± 1.872 136
Note: ATO (atovaquone) was applied as positive control.
aValues are the means of at least three independent
experiments ± standard deviation. They were derived from concentration–
response curves obtained by measuring the percentage of vital cells
relative to untreated controls after 72 hr.
bSelectivity index (SI; IC50/EC50) calculated from the corresponding IC50
values for the Vero cells and the EC50 values against T. gondii.
TABLE 2 Effective concentrations EC50
(in µM) of test compounds 1a–g when
applied to promastigotes and amastigotes
of Leishmania majora
Compd.
EC50
promastigotes EC50 amastigotes
SI Vero/
promastigotesb
SI Vero/
amastigotesb
1a 0.37 ± 0.042 0.11 ± 0.008 1.0 3.32
1b 0.42 ± 0.035 0.22 ± 0.065 1.57 3.01
1c 0.45 ± 0.061 0.19 ± 0.057 1.02 2.41
1d 0.33 ± 0.017 0.38 ± 0.038 2.16 1.89
1e 3.11 ± 0.983 0.43 ± 0.097 1.78 12.8
1f 0.31 ± 0.072 0.46 ± 0.086 1.86 1.25
1g 1.34 ± 0.349 0.26 ± 0.074 0.16 0.85
AmB 0.83 ± 0.164 0.47 ± 0.089 9.6 16.4
Note: AmB (amphotericin B) was applied as positive control.
aValues are the means of at least three independent experiments ± standard deviation. They were
derived from concentration–response curves obtained by measuring the percentage of vital cells
relative to untreated controls after 72 hr.
bSelectivity index (SI; IC50/EC50) calculated from the corresponding IC50 values for the Vero cells
(Table 1) and the EC50 values against L. major.
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3 | CONCLUSIONS
The evaluation of a series of NHC gold(I) complexes against patho-
genic parasites such as T. gondii, T. b. brucei and L. major led to pro-
mising results. Both high activities and considerable selectivities were
observed. The ferrocene derivatives 1a and 1b, in particular, were
highly active against all tested parasites. The anisyl‐NHC
derivatives 1d and 1f exhibited remarkable activities against L. major
promastigotes, which is worthy of note as most of the other tested
complexes were more active against L. major amastigotes, which is also
more typical of established antileishmanial drugs and drug candidates
currently in the pipeline. More research into the mechanisms of action
and their structure–activity dependencies is necessary to pinpoint the
reason for these peculiar differences. According to present knowledge,
investigational applications of some of the tested gold complexes for
the treatment of cutaneous leishmaniasis (i.e., L. major infection)
appear promising, as do their combinations with approved
antiparasitic drugs such as pentamidine or miltefosine to reduce the
necessary doses and possible side‐effects.
4 | EXPERIMENTAL
4.1 | Chemistry
4.1.1 | General
All starting compounds were purchased from Aldrich. The known
complexes 1a and 1d–g and the TosMIC reagents 2b and 2c were
prepared according to literature procedures.[18,19,22] The analytical
data of these compounds were in agreement with the published data.
The following instruments were applied for this study: melting points
(uncorrected), Gallenkamp; infrared (IR) spectra, Perkin–Elmer
Spectrum One FT‐IR spectrophotometer with ATR‐sampling unit;
nuclear magnetic resonance spectra, Bruker Avance 300 spectro-
meter; chemical shifts are given in parts per million (δ) downfield
from tetramethylsilane as internal standard; mass spectra, Varian
MAT 311A (EI), UPLC/Orbitrap (ESI); microanalyses, Perkin–Elmer
2400 CHN elemental analyzer.
The compound codes together with the nuclear magnetic
resonance (NMR) spectra of the new compounds 1b and 1c are
provided as Supporting Information.
1‐Ethyl‐5‐ferrocenyl‐4‐(3,4,5‐trimethoxyphenyl)‐imidazole (3b)
Ferrocenecarboxaldehyde (90mg, 0.42mmol) was dissolved in EtOH
and EtNH2 (2M in THF, 1.05ml, 2.10mmol) and AcOH (150 µl,
2.63mmol) were added. The reaction mixture was stirred under reflux
for 1 hr. Compound 2b (159mg, 0.44mmol) and K2CO3 (500mg,
3.62mmol) were added, and the reaction mixture was stirred under
reflux for 2 hr. The solvent was evaporated, and the residue was
suspended in ethyl acetate, washed with water, dried over Na2SO4,
filtered, and the filtrate was concentrated in vacuum. The residue was
purified by column chromatography (silica gel 60, ethyl acetate/
methanol 9:1). Yield: 138mg (0.31mmol, 74%); brown oil; νmax(ATR)/cm
3,087, 3,004, 2,958, 2,931, 2,831, 1,585, 1,511, 1,459, 1,432, 1,413,
1,390, 1,354, 1,344, 1,286, 1,235, 1,198, 1,185, 1,124, 1,062, 1,033,
1,010, 959, 885, 842, 818, 770, 743, 732, 697, 664, 651, 641, and 626;
1H NMR (300MHz, CDCl3) δ 1.58 (3H, t, J =7.3Hz, CH3), 3.75 (6H, s,
2 ×OCH3), 3.83 (3H, s, OCH3), 4.0–4.1 (5H, m, Fc–H), 4.2–4.3 (4H, m,
Fc–H), 4.51 (2H, q, J = 7.3Hz, CH2), 6.69 (2H, s, Ar–H), and 7.59 (1H, s,
imidazole–H); 13C NMR (75.5MHz, CDCl3) δ 17.1 (CH3), 39.8 (CH2),
56.0 (OCH3), 60.9 (OCH3), 66.6, 68.2, 69.2, 75.4 (Fc–C), 105.8, 113.2,
124.1, 130.4, 131.0, 136.1, 136.6, 136.9, 140.1 (Ar–C or imidazole–C),
152.7 (Ar–COCH3), and 153.2 (Ar–COCH3); m/z (%) 447 (82) [M
+], 446
(100) [M+], 415 (7), 381 (38), 294 (13), 252 (15), 121 (23), and 56 (14).
1‐Ethyl‐4‐anisyl‐5‐ferrocenylimidazole (3c)
Ferrocenecarboxaldehyde (90mg, 0.42mmol) was dissolved in EtOH
and EtNH2 (2M in THF, 1.05ml, 2.10mmol) and AcOH (150 µl,
2.63mmol) were added. The reaction mixture was stirred under reflux
for 1 hr. Compound 2c (133mg, 0.44mmol) and K2CO3 (500mg,
3.62mmol) were added and the reaction mixture was stirred under re-
flux for 2 hr. The solvent was evaporated and the residue was suspended
in ethyl acetate, washed with water, dried over Na2SO4, filtered, and the
filtrate was concentrated in vacuum. The residue was purified by column
chromatography (silica gel 60, ethyl acetate/methanol 9:1). Yield: 128mg
(0.33mmol, 79%); brown oil; νmax(ATR)/cm 3,093, 2,973, 2,935, 2,835,
1,613, 1,577, 1,562, 1,516, 1,456, 1,412, 1,378, 1,350, 1,290, 1,242,
1,199, 1,173, 1,105, 1,030, 1,001, 949, 876, 832, 744, 723, 707, 663,
635, and 600; 1H NMR (300MHz, CDCl3) δ 1.54 (3H, t, J =7.3Hz, CH3),
3.80 (3H, s, OCH3), 4.0–4.1 (5H, m, Fc–H), 4.2–4.3 (4H, m, Fc–H), 4.45
(2H, q, J =7.3Hz, CH2), 6.84 (2H, d, J=8.9Hz, Ar–H), 7.39 (2H, d,
J=8.9Hz, Ar–H), and 7.58 (1H, s, imidazole–H); 13C NMR (75.5MHz,
CDCl3) δ 17.0 (CH3), 40.0 (CH2), 60.4 (OCH3), 68.1, 68.9, 69.1, 75.7
(Fc–C), 113.3, 113.8, 123.6, 127.6, 128.4, 128.8, 130.0, 132.1, 136.1,
136.3, 140.0 (Ar–C or imidazole–C), 158.5 (Ar–COCH3); m/z (%) 386
(100) [M+], 321 (47), 308 (47), 264 (22), 193 (26), 121 (31), and 56 (21).
TABLE 3 Inhibitory concentrations IC50 (in µM) of test compounds
1a–c and 1e when applied to Trypanosoma brucei brucei cells and
human HeLa cellsa
Compd. IC50 (T. b. brucei) IC50 (HeLa)
SI (HeLa/T. b.
brucei)b
1a 0.00093c 0.138c 148c
1b 0.005 ± 0.001 0.840 ± 0.170 168
1c 0.028 ± 0.005 0.277 ± 0.035 9.89
1e 0.003c 0.231c 77c
Pentamidine 0.000042c 1.47c 35,000c
aValues are the means of at least three independent
experiments ± standard deviation. They were derived from concentration–
response curves obtained by measuring the percentage of vital cells
relative to untreated controls after 72 hr.
bSelectivity index (SI) calculated from the corresponding IC50 values for
the HeLa cells and the IC50 values for T. b. brucei.
cValue is taken from Reference [12].
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1,3‐Diethyl‐4‐ferrocenyl‐5‐(3,4,5‐trimethoxyphenyl)‐imidazolium
iodide (4b)
Compound 3b (130mg, 0.29mmol) was dissolved in MeCN (15ml) and
iodoethane (1.0ml, 12.4mmol) was added. The reaction mixture was
stirred at 85°C for 24 hr. The solvent was evaporated and the residue
was dried in vacuum. Yield: 170mg (0.28mmol, 97%); brown oil;
νmax(ATR)/cm 3,133, 3,037, 2,975, 2,937, 2,835, 1,580, 1,566, 1,510,
1,488, 1,463, 1,444, 1,429, 1,412, 1,390, 1,353, 1,343, 1,294, 1,238,
1,196, 1,159, 1,122, 1,087, 1,060, 1,032, 1,021, 1,001, 962, 918, 887, 840,
826, 816, 800, 777, 727, 674, 663, 623, and 600; 1H NMR (300MHz,
CDCl3) δ 1.49 (3H, t, J=7.3Hz, CH3), 1.76 (3H, t, J=7.3Hz, CH3), 3.83
(6H, s, 2 ×OCH3), 3.92 (3H, s, OCH3), 4.0–4.1 (5H, m, Fc–H), 4.1–4.2 (2H,
m, Fc–H), 4.20 (2H, q, J=7.3Hz, CH2), 4.3–4.4 (2H, m, Fc–H), 4.72 (2H, q,
J=7.3Hz, CH2), 6.53 (2H, s, Ar–H), and 10.30 (1H, s, imidazolium–H);
13C
NMR (75.5MHz, CDCl3) δ 15.9 (CH3), 16.5 (CH3), 43.4 (CH2), 56.6
(OCH3), 61.1 (OCH3), 67.3, 68.7, 69.3, 69.7, 69.8, 70.0, 70.4, 80.3 (Fc–C),
106.3, 108.3, 120.9, 129.7, 130.1, 130.2, 135.7, 138.0, 140.0 (Ar–C or
imidazolium–C), 154.0 (Ar–COCH3), and 154.4 (Ar–COCH3);m/z (%) 474
(2) [M+], 445 (18), 142 (42), 127 (21), and 66 (100).
1,3‐Diethyl‐4‐anisyl‐5‐ferrocenylimidazolium iodide (4c)
Compound 3c (127mg, 0.33mmol) was dissolved in MeCN (15ml) and
iodoethane (1.0ml, 12.4mmol) was added. The reaction mixture was
stirred at 85°C for 24 hr. The solvent was evaporated and the residue
was dried in vacuum. Yield: 179mg (0.33mmol, 100%); brown oil;
νmax(ATR)/cm 3,439, 2,977, 2,934, 2,837, 1,616, 1,599, 1,562, 1,519,
1,487, 1,455, 1,411, 1,386, 1,343, 1,292, 1,249, 1,175, 1,106, 1,022,
1,006, 963, 919, 883, 838, 768, 724, 639, 626, and 616; 1H NMR
(300MHz, CDCl3) δ 1.40 (3H, t, J = 7.3 Hz, CH3), 1.71 (3H, t, J = 7.3 Hz,
CH3), 3.84 (3H, s, OCH3), 3.92 (3H, s, OCH3), 3.9–4.0 (5H, m, Fc–H),
4.0–4.1 (4H, m, Fc–H), 4.2–4.3 (2H, m, CH2), 4.66 (2H, q, J = 7.3 Hz,
CH2), 7.01 (2H, d, J = 8.9 Hz, Ar–H), 7.23 (2H, d, J = 8.9Hz, Ar–H), and
10.23 (1H, s, imidazolium–H); 13C NMR (75.5MHz, CDCl3) δ 15.6
(CH3), 16.3 (CH3), 43.1 (CH2), 43.4 (CH2), 55.4 (OCH3), 67.3, 68.7,
69.2, 69.5, 69.6, 70.1, 80.3 (Fc–C), 106.5, 114.6, 115.1, 117.6, 130.0,
130.1, 131.6, 131.8, 132.4, 135.4, 137.9, 147.0 (Ar–C or imidazolium–
C), and 161.2 (Ar–COCH3); m/z (%) 415 (53) [M
+], 401 (60), 387 (100),
373 (55), 348 (35), 309 (27), 186 (72), 142 (37), 121 (34), and 66 (78).
1,3‐Diethyl‐4‐ferrocenyl‐5‐(3,4,5‐trimethoxyphenyl)‐imidazolium
tetrafluoroborate (5b)
Compound 4b (170mg, 0.28mmol) was dissolved in acetone (15ml)
and NaBF4 (47mg, 0.43mmol) was added. The reaction mixture was
stirred at room temperature for 24 hr. The solution was filtered over
MgSO4, the filtrate was concentrated and dried in vacuum. Yield:
157mg (0.28mmol, 100%); brown oil; νmax(ATR)/cm 2,987, 2,928,
2,828, 1,583, 1,568, 1,511, 1,489, 1,458, 1,428, 1,412, 1,393, 1,351,
1,296, 1,240, 1,197, 1,164, 1,124, 1,107, 1,032, 1,010, 921, 889, 858,
825, 778, 727, 675, 642, and 627; 1H NMR (300MHz, CDCl3) δ 1.47
(3H, t, J = 7.3 Hz, CH3), 1.74 (3H, t, J = 7.3 Hz, CH3), 3.81 (6H, s,
2 × OCH3), 3.89 (3H, s, OCH3), 4.0–4.1 (5H, m, Fc–H), 4.1–4.2 (4H, m,
Fc–H), 4.3–4.4 (2H, m, CH2), 4.70 (2H, q, J = 7.3 Hz, CH2), 6.54 (2H, s,
Ar–H), and 10.18 (1H, s, imidazolium–H); 13C NMR (75.5MHz,
CDCl3) δ 15.8 (CH3), 16.4 (CH3), 43.4 (CH2), 56.6 (OCH3), 61.0
(OCH3), 67.3, 68.6, 69.2, 69.6, 70.0, 70.3 (Fc–H), 106.4, 108.3, 120.9,
130.0, 130.1, 135.4, 137.8, 139.8 (Ar–C or imidazolium–C), 153.8
(Ar–COCH3), and 154.1 (Ar–COCH3).
1,3‐Diethyl‐4‐anisyl‐5‐ferrocenylimidazolium tetrafluoroborate (5c)
Compound 4c (166mg, 0.31mmol) was dissolved in acetone (15ml)
and NaBF4 (51mg, 0.47 mmol) was added. The reaction mixture was
stirred at room temperature for 24 hr. The solution was filtered over
MgSO4, the filtrate was concentrated and dried in vacuum. Yield:
156mg (0.31mmol, 100%); brown oil; νmax(ATR)/cm 3,417, 2,976,
2,935, 2,836, 1,616, 1,599, 1,562, 1,519, 1,487, 1,456, 1,411, 1,386,
1,343, 1,292, 1,249, 1,175, 1,106, 1,022, 1,006, 963, 919, 883, 838,
768, 724, 639, and 615; 1H NMR (300MHz, CDCl3) δ 1.39 (3H, t,
J = 7.3 Hz, CH3), 1.71 (3H, t, J = 7.3 Hz, CH3), 3.84 (3H, s, OCH3),
3.9–4.0 (5H, m, Fc–H), 4.0–4.1 (4H, m, Fc–H), 4.2–4.3 (2H, m, CH2),
4.65 (2H, q, J = 7.3 Hz, CH2), 7.01 (2H, d, J = 8.9 Hz, Ar–H), 7.23 (2H,
d, J = 8.9 Hz, Ar–H), and 10.19 (1H, s, imidazolium–H); 13C NMR
(75.5MHz, CDCl3) δ 15.6 (CH3), 16.3 (CH3), 43.0 (CH3), 43.4 (CH3),
55.5 (OCH3), 67.3, 68.7, 69.2, 69.3, 69.5, 69.6, 70.1, 80.4 (Fc–H),
106.5, 114.6, 115.1, 117.6, 130.0, 130.1, 131.6, 131.8, 132.0. 132.4,
135.3, 137.9 (Ar–C or imidazolium–C), and 161.3 (Ar–COCH3).
Bis‐[1,3‐diethyl‐4‐ferrocenyl‐5‐(3,4,5‐trimethoxyphenyl)‐imidazol‐
2‐ylidene]gold(I) (1b)
Compound 5b (157mg, 0.28 mmol) was dissolved in CH2Cl2/MeOH
(1:1, 30ml) and Ag2O (108mg, 0.47mmol) was added. The reaction
mixture was stirred at room temperature for 5 hr. Au(DMS)Cl (41mg,
0.14mmol) was added and the reaction mixture was stirred at room
temperature for 24 hr. The suspension was filtered, the filtrate was
concentrated in vacuum and the residue was redissolved in CH2Cl2,
filtered over MgSO4/celite. The filtrate was concentrated and the
remainder was recrystallized from CH2Cl2/n‐hexane and dried in
vacuum. Yield: 136mg (0.11mmol, 79%); brown solid of mp
176–178°C; νmax(ATR)/cm 2,933, 1,580, 1,509, 1,460, 1,411, 1,346,
1,327, 1,287, 1,236, 1,185, 1,165, 1,124, 1,107, 1,047, 1,030, 1,002,
916, 886, 822, 779, 727, and 670; 1H NMR (300MHz, CDCl3)
δ 1.3–1.5 (6H, m, 2 × CH3), 1.6–1.8 (6H, m, 2 × CH3), 3.83 (12H, s,
4 ×OCH3), 3.9–4.0 (6H, m, 2 ×OCH3), 4.0–4.3 (22H, m, Fc–H,
2 × CH2), 4.6–4.7 (4H, m, 2 × CH2), and 6.51 (4H, s, Ar–H);
13C
NMR (75.5MHz, CDCl3) δ 17.7 (CH3), 18.2 (CH3), 44.1 (CH2), 44.3
(CH2), 56.5 (OCH3), 61.0 (OCH3), 65.1, 68.4, 69.1, 69.2, 69.5, 72.4
(Fc–H), 108.1, 108.4, 123.6, 128.7, 129.2, 130.5 (Ar–C or
imidazolium–C), 149.9 (Ar–COCH3), 153.6 (Ar–COCH3), and 182.8
(Au–C); m/z (ESI, %) 1,145.0 (80) [M+] and 475.2 (100). Anal calcd.
C52H60AuBF4Fe2N4O6: C, 50.67; H, 4.91; N, 4.55; Found, C, 50.79; H,
4.99; N, 4.60%.
Bis‐[1,3‐diethyl‐4‐anisyl‐5‐ferrocenylimidazol‐2‐ylidene]gold(I) (1c)
Compound 5c (156mg, 0.31mmol) was dissolved in CH2Cl2/MeOH
(1:1, 20ml) and Ag2O (120mg, 0.52mmol) was added. The reaction
mixture was stirred at room temperature for 5 hr. Au(DMS)Cl (45mg,
0.16mmol) was added and the reaction mixture was stirred at room
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temperature for 24 hr. The suspension was filtered, the filtrate was
concentrated in vacuum and the residue was redissolved in CH2Cl2,
filtered over MgSO4/celite. The filtrate was concentrated and the
remainder was recrystallized from CH2Cl2/n‐hexane and dried in
vacuum. Yield: 127mg (0.114mmol, 71%); brown solid of mp
190–193°C; νmax(ATR)/cm 2,960, 2,933, 2,872, 2,841, 1,621, 1,599,
1,573, 1,517, 1,462, 1,414, 1,380, 1,346, 1,306, 1,290, 1,250, 1,177,
1,106, 1,046, 1,027, 970, 913, 885, 837, 815, 790, 773, 727, and 645;
1H NMR (300MHz, CDCl3) δ 1.3–1.4 (6H, m, 2 ×CH3), 1.6–1.7 (6H, m,
2 ×CH3), 3.88 (6H, s, 2 ×OCH3), 4.0 –4.1 (10H, m, Fc–H), 4.1–4.2 (8H,
m, Fc–H), 4.2–4.3 (4H, m, 2 ×CH2), 4.69 (4H, q, J = 7.3Hz, 2 ×CH2), 7.03
(4H, d, J = 8.8Hz, Ar–H), and 7.2–7.3 (4H, m, Ar–H); 13C NMR
(75.5MHz, CDCl3) δ 17.3 (CH3), 18.2 (CH3), 44.1 (CH2), 55.4 (OCH3),
67.0, 68.4, 69.1, 69.2, 69.4, 69.7, 72.5, 81.5 (Fc–C), 109.0, 114.4, 114.7,
114.9, 119.4, 120.3, 128.8, 130.0, 130.4, 131.5, 131.8, 132.0. 132.4,
134.6 (Ar–C or imidazolium–C, 160.7 (Ar–COCH3), and 182.3 (Au–C);
m/z (ESI, %) 1,025.0 (100) [M+], 946.9 (45), and 506.6 (25). Anal calcd.
C48H52AuBF4Fe2N4O2: C, 51.83; H, 4.71; N, 5.04; Found, C, 51.95; H,
4.80; N, 5.11%.
4.2 | Biological assays
4.2.1 | Leishmania major cell isolation, culture
conditions, and assays
Promastigotes of L. major were isolated from a Saudi male patient in
February 2016 and maintained at 26°C in Schneider's Drosophila
medium (Invitrogen) supplemented with 10% heat‐inactivated fetal
bovine serum (FBS; Invitrogen) and antibiotics in a tissue culture
flask with weekly transfers. Promastigotes were cryopreserved in
liquid nitrogen at concentrations of 3 × 106 parasite/ml. The
virulence of L. major parasites was maintained by passing in female
BALB/c mice by injecting hind footpads with 1 × 106 stationary‐phase
promastigotes. After 8 weeks, L. major amastigotes were isolated
from mice. Isolated amastigotes were transformed to promastigote
forms by culturing at 26°C in Schneider's medium supplemented
with 10% FBS and antibiotics. For infection, amastigote‐derived
promastigotes with less than five in vitro passages were used. Male
and female BALB/c mice were obtained from Pharmaceutical College,
King Saud University, Kingdom of Saudi Arabia, and maintained in
specific pathogen‐free facilities.
To evaluate the activity of test compounds against L. major
promastigotes, promastigotes from logarithmic‐phase cultured in
phenol red‐free RPMI‐1640 medium (Invitrogen) with 10% FBS were
suspended on 96‐wells plates to yield 106 cells/ml (200 µl/well) after
hemocytometer counting. Compounds were added to obtain the final
concentrations (50, 25, 12.5, 6.25, 3.13, 1.65, and 0.75 µg/ml). Negative
control wells containing cultures with dimethyl sulfoxide (DMSO; 1%)
and without compound and positive control wells containing cultures
with decreasing concentration of AmB (reference compound, 50, 25,
12.5, 6.25, 3.13, 1.65, 0.75 µg/ml) were used. Plates were incubated at
26°C for 72 hr to evaluate the antiproliferative effect. The number of
viable promastigotes were assessed by colorimetric method using
the tetrazolium salt colorimetric assay (3‐[4,5‐dimethylthiazol‐2‐yl]‐2,5‐
diphenyltetrazolium bromide, MTT). It measures the reduction of the
MTT component into an insoluble formazan product. This colored
product was solubilized by adding a detergent solution to lyse the cells.
The samples were analyzed using an enzyme‐linked immunosorbent
assay reader at 570 nm. Obtained EC50 values resulted from three
independent experiments.[23]
To evaluate the activity of test compounds against amastigotes in
macrophages, peritoneal macrophages from female BALB/c mice
(6–8 weeks of age) were collected by aspiration, then 5 × 104 cells per
well were seeded on 96‐wells plates in phenol red‐free Roswell Park
Memorial Institute‐1640 (RPMI‐1640) medium with 10% FBS for 4 hr
at 37°C in 5% CO2 atmosphere to promote cell adhesion. The medium
was discarded and washed with phosphate‐buffered saline (PBS).
200 µl containing L. major promastigotes solution (at a ratio of 10
promastigotes to 1 macrophage in RPMI‐1640 medium with 10% FBS)
was added per well. Plates were incubated for 24 hr at 37°C in a
humidified 5% CO2 atmosphere to allow infection and amastigote
differentiation. Then, the infected macrophages were washed three
times with PBS to remove the free promastigotes and overlaid with
fresh phenol red‐free RPMI‐1640 medium containing compounds at
final concentrations (50, 25, 12.5, 6.25, 3.13, 1.65, and 0.75 µg/ml)
were added and cells were incubated at 37°C in humidified 5% CO2
atmosphere for 72 hr. Negative control containing cultures with
DMSO (1%) and without compounds and positive control wells
containing cultures with decreasing concentration of AmB (reference
compound, 50, 25, 12.5, 6.25, 3.13, 1.65, and 0.75 µg/ml) were used.
The percentage of infected macrophages were evaluated
microscopically after removing medium, washing, fixation, and Giemsa
staining. Obtained EC50 values resulted from three independent
experiments (for the EC50 calculation see Section 4.2.2.).
[23]
4.2.2 | Toxoplasma gondii cell line, culture conditions,
and assay
Serial passages of the cell line Vero (ATCC® CCL81™) were used for
the cultivation of T. gondii tachyzoites of the RH strain (a gift from Dr.
Saeed El‐Ashram, State Key Laboratory for Agrobiotechnology, China
Agricultural University, Beijing, China). Vero cells were cultured by
using a complete RPMI‐1640 medium with heat‐inactivated 10% FBS
in a humidified 5% CO2 atmosphere at 37°C. For the cultivation of
the Vero cells, 96‐well plates (5 × 103 cells per well in 200 µl
RPMI‐1640 medium) were used and then the cells were incubated at
37°C and 5% CO2 for 1 day, followed by removal of medium and
washing the cells with PBS. Then, RPMI‐1640 medium with 2% FBS
containing tachyzoites (RH strain) of T. gondii at a ratio of 5
(parasite) to 1 (Vero cells) was added. After incubation at 37°C and
5% CO2 for 5 hr, cells were washed with PBS and then treated as
described below.
Negative control (control): Wells containing cultures with DMSO
(1%) without test compound.
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Experimental: Medium+ compounds (dissolved in DMSO) (50, 25,
12.5, 6.25, 3.13, 1.65, and 0.75 µg/ml).
Positive control (reference drug): Medium + ATO (dissolved in
DMSO; 50, 25, 12.5, 6.25, 3.13, 1.65, and 0.75 µg/ml).
After incubation at 37°C and 5% CO2 for 72 hr, the cells were
stained with 1% toluidine blue after washing with PBS and fixation
in 10% formalin. The cells were examined under an inverted
photomicroscope to determine the infection index (number of cells
infected from 200 cells tested) of T. gondii. The following equation
was used for the calculation of the observed inhibition (in %):
( ) = (  –  )/( ) ×I I IInhibition % 100,Control Experimental Control
where IControl refers to the infection index of untreated cells and
IExperimental refers to the infection index of cells treated with test
compounds.
Then effects of test compounds on parasite growth were
expressed as EC50 (effective concentration at 50%) values. Obtained
EC50 values resulted from three independent experiments.
[24]
4.2.3 | Trypanosoma cell line and culture conditions
Cultivation of the T. b. brucei bloodstream‐form cell strain Lister 427
was carried out in HMI‐9 medium, pH 7.5, supplemented with 10%
FBS at 37°C in a humidified 5% CO2 atmosphere.
[25]
4.2.4 | Alamar Blue (AB) assay
Viable cells after treatment with drug candidates were identified via
the AB assay.[26–29] Pink resorufin is formed in intact cells from the
irreversible reaction of the blue dye resazurin and NADH. T. b. brucei
cells (8,000/well) were seeded on 96‐well microplates, test
compounds (dissolved in DMSO) were added and the cells were
incubated for 72 hr (5% CO2, 95% humidity, 37°C). AB reagent (10 µl
of 500 µM resazurin sodium salt in PBS) was added and the cells
were incubated for an additional 4 hr at 37°C. Fluorescence
(extinction at 544 nm, emission at 590 nm) was determined on an
Omega Fluostar (BMG Labtech) fluorescence plate reader. The IC50
values were determined with the Quest Graph™ IC50 Calculator (AAT
Bioquest Inc.).
4.2.5 | In vitro cytotoxicity assay
MTT assay was carried out for cytotoxicity evaluation of compounds.
Briefly, Vero cells were cultured in 96‐well plates (5 × 103 cells per
well per 200 µl) for 24 hr in RPMI‐1640 medium with 10% FBS and
5% CO2 at 37°C. Cells were washed with PBS and treated with test
compounds for 72 hr at varying concentrations (50, 25, 12.5, 6.25,
3.13, 1.65, and 0.75 µg/ml) in medium with 10% FBS. As a negative
control, cells were treated with the medium in 2% FBS. Thereafter,
the supernatant was removed and 100ml RPMI‐1640 medium con-
taining 10ml MTT (5mg/ml) was added and incubated for 4 hr. After
that, the supernatant was removed and 200ml DMSO was added to
dissolve the formazan. FLUOstar OPTIMA spectrophotometer was
applied for colorimetric analysis (λ = 540 nm). Cytotoxic effects were
expressed by IC50 values (concentration that caused a 50% reduction
in viable cells). Obtained IC50 values resulted from three independent
experiments.[30,31]
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